- Home
- STTK vs BAFN Comparison
STTK vs BAFN Comparison
Compare STTK & BAFN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- BAFN
- Stock Information
- Founded
- STTK 2016
- BAFN 1999
- Country
- STTK United States
- BAFN United States
- Employees
- STTK N/A
- BAFN N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- BAFN Savings Institutions
- Sector
- STTK Health Care
- BAFN Finance
- Exchange
- STTK Nasdaq
- BAFN Nasdaq
- Market Cap
- STTK 56.8M
- BAFN 55.4M
- IPO Year
- STTK 2020
- BAFN N/A
- Fundamental
- Price
- STTK $1.23
- BAFN $15.96
- Analyst Decision
- STTK Hold
- BAFN
- Analyst Count
- STTK 3
- BAFN 0
- Target Price
- STTK $2.00
- BAFN N/A
- AVG Volume (30 Days)
- STTK 127.4K
- BAFN 6.3K
- Earning Date
- STTK 02-27-2025
- BAFN 01-30-2025
- Dividend Yield
- STTK N/A
- BAFN 2.01%
- EPS Growth
- STTK N/A
- BAFN 134.19
- EPS
- STTK N/A
- BAFN 2.62
- Revenue
- STTK $6,435,000.00
- BAFN $83,769,000.00
- Revenue This Year
- STTK $313.04
- BAFN N/A
- Revenue Next Year
- STTK N/A
- BAFN N/A
- P/E Ratio
- STTK N/A
- BAFN $6.04
- Revenue Growth
- STTK 382.75
- BAFN 10.60
- 52 Week Low
- STTK $0.94
- BAFN $10.40
- 52 Week High
- STTK $11.76
- BAFN $17.50
- Technical
- Relative Strength Index (RSI)
- STTK 52.10
- BAFN 68.23
- Support Level
- STTK $1.11
- BAFN $14.41
- Resistance Level
- STTK $1.36
- BAFN $15.74
- Average True Range (ATR)
- STTK 0.11
- BAFN 0.85
- MACD
- STTK 0.01
- BAFN 0.13
- Stochastic Oscillator
- STTK 56.67
- BAFN 65.11
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About BAFN BayFirst Financial Corp.
BayFirst Financial Corp is a one bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios.